AR042354A1 - Aplicacion de inhibidores de recaptura intestinal del acido biliar para la prevencion y el tratamiento de la enfermedad de alzheimer - Google Patents

Aplicacion de inhibidores de recaptura intestinal del acido biliar para la prevencion y el tratamiento de la enfermedad de alzheimer

Info

Publication number
AR042354A1
AR042354A1 ARP030104540A ARP030104540A AR042354A1 AR 042354 A1 AR042354 A1 AR 042354A1 AR P030104540 A ARP030104540 A AR P030104540A AR P030104540 A ARP030104540 A AR P030104540A AR 042354 A1 AR042354 A1 AR 042354A1
Authority
AR
Argentina
Prior art keywords
alzheimer
disease
prevention
treatment
application
Prior art date
Application number
ARP030104540A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR042354A1 publication Critical patent/AR042354A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Aplicación de inhibidores de recaptura intestinal del ácido biliar para la prevención y el tratamiento de la enfermedad de alzheimer, en su caso en asociación con un inhibidor de HMG-CoA-reductasa, un inhibidor de la captura de colesterol, un inhibidor de la síntesis de colesterol o un inhibidor de las APP-secretasas.
ARP030104540A 2002-12-12 2003-12-10 Aplicacion de inhibidores de recaptura intestinal del acido biliar para la prevencion y el tratamiento de la enfermedad de alzheimer AR042354A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
AR042354A1 true AR042354A1 (es) 2005-06-15

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104540A AR042354A1 (es) 2002-12-12 2003-12-10 Aplicacion de inhibidores de recaptura intestinal del acido biliar para la prevencion y el tratamiento de la enfermedad de alzheimer

Country Status (22)

Country Link
EP (1) EP1572174A1 (es)
JP (1) JP2006514063A (es)
KR (1) KR20050084250A (es)
CN (1) CN1726016A (es)
AR (1) AR042354A1 (es)
AU (1) AU2003296802A1 (es)
BR (1) BR0317280A (es)
CA (1) CA2507945A1 (es)
CO (1) CO5700712A2 (es)
FR (1) FR2848452B1 (es)
HR (1) HRP20050534A2 (es)
MA (1) MA27500A1 (es)
MX (1) MXPA05005556A (es)
NO (1) NO20053341L (es)
NZ (1) NZ540496A (es)
PE (1) PE20040770A1 (es)
PL (1) PL377110A1 (es)
RS (1) RS20050420A (es)
RU (1) RU2005121909A (es)
TW (1) TW200503707A (es)
WO (1) WO2004062652A1 (es)
ZA (1) ZA200504656B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP1680120A2 (en) 2003-11-03 2006-07-19 Probiodrug AG Combinations useful for the treatment of neuronal disorders
JP4996926B2 (ja) 2004-02-05 2012-08-08 プロビオドルグ エージー グルタミニルシクラーゼの新規の阻害剤
CA2589102C (en) 2004-11-02 2013-08-13 Northwestern University Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
WO2007127474A2 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
CA2687289C (en) * 2007-05-22 2015-09-15 Otsuka Pharmaceutical Co., Ltd. A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
EP2771003B1 (en) 2011-10-28 2017-04-19 Lumena Pharmaceuticals LLC Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP2770990A4 (en) * 2011-10-28 2015-03-11 Lumena Pharmaceuticals Inc Gallic acid refluxing agent for the treatment of hypertension and chronic liver disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
ATE231723T1 (de) * 1991-02-22 2003-02-15 Howard K Shapiro Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe
AU3585397A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
CA2311356C (en) * 1998-01-28 2004-07-13 Warner-Lambert Company Method for treating alzheimer's disease
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
AU2001233299A1 (en) * 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
KR20050084250A (ko) 2005-08-26
PE20040770A1 (es) 2004-12-10
WO2004062652A1 (fr) 2004-07-29
HRP20050534A2 (en) 2006-11-30
FR2848452B1 (fr) 2007-04-06
BR0317280A (pt) 2005-11-08
CA2507945A1 (fr) 2004-07-29
RU2005121909A (ru) 2006-01-20
NO20053341L (no) 2005-09-07
CN1726016A (zh) 2006-01-25
NZ540496A (en) 2008-04-30
JP2006514063A (ja) 2006-04-27
AU2003296802A1 (en) 2004-08-10
MXPA05005556A (es) 2005-07-26
MA27500A1 (fr) 2005-08-01
RS20050420A (en) 2007-04-10
ZA200504656B (en) 2006-08-30
EP1572174A1 (fr) 2005-09-14
NO20053341D0 (no) 2005-07-08
FR2848452A1 (fr) 2004-06-18
PL377110A1 (pl) 2006-01-23
TW200503707A (en) 2005-02-01
CO5700712A2 (es) 2006-11-30

Similar Documents

Publication Publication Date Title
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
GB0223040D0 (en) Therapeutic compounds
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
PT1522314E (pt) Medicamentos para doenças causadas pela contracção ou dilatação vascular
NO20053341L (no) Hindring og behandling av Alzheimers sykdom.
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
MY147175A (en) Method for preventing or treating the development of respiratory allergies
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
IS8004A (is) Aðferð við meðhöndlun á vægri vitsmunaskerðingu og til að fyrirbyggja eða tefja Alzheimers-sjúkdóminn
NO20063963L (no) Multipartikulaere 0-desmetylvenlafaksinsalter og anvendelser derav
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
MX2007006279A (es) Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa.
EA200501479A1 (ru) Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией
ATE410235T1 (de) Behandlung von ballastwasser
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
WO2006102126A3 (en) Inhibitors of isoprenylcysteine carboxyl methyltransferase
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
NO20053247D0 (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal